The development of novel FASN inhibitors is underway, and preliminary clinical trial data on TVB-2640 demonstrate its potential to mitigate tumor response in patients with non-small cell lung cancer and breast cancer when used in combination with paclitaxel (Jones and Infante, 2015). This evidence concerns the gene FASN and breast cancer.